𝔖 Bobbio Scriptorium

✦ LIBER ✦

387 PUBLICATION Potential health economic benefits of adjuvant (A) trastuzumab (H) therapy of node-positive (N+) her-2+breast cancer (BC)

Book ID: 118622967
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 141 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)80685-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High Ki-67 score is indicative of a grea

High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer

✍ Criscitiello, Carmen; Disalvatore, Davide; De Laurentiis, Michele; Gelao, Lucia; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 331 KB

263 ORAL Doxorubicin and cyclophosphamid

263 ORAL Doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with or without trastuzumab (H) as adjuvant therapy for patients with HER2-positive operable breast cancer (BC): combined analysis of NSABP B-31 and NCCTG N9831

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Cardiac safety analysis of the first sta

Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)

✍ C Geyer; J Bryant; E Romond; E Tan-Chiu; M Ewer; D Keefe; R Shannon; G Yothers; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 541 KB